Ongoing Assessments & Recent Research.
Easy access to our work
Amyotrophic Lateral Sclerosis (ALS)
Aug 2022Beta Thalassemia
Jun 2022COVID-19
Apr 2022Hemophilia A and B
Nov 2022Obesity Management
Sep 2022Featured News & Insights.
Learn about our latest work.
ICER Publishes Protocol for Annual Assessment of Drug Coverage Policies That Present Barriers to Fair Access
ICER will evaluate whether the 15 largest US commercial payers, the 2 largest state health exchange plans, and the Department of Veterans Affairs have formularies and procedures that provide appropriate access to the prescription drugs reviewed by ICER in 2020.
05/23/2022ICER Publishes Final Evidence Report and Policy Recommendations on Outpatient Treatments for COVID-19
Independent appraisal committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit for molnupiravir over symptomatic care alone; Paxlovid and fluvoxamine receive more favorable votes.
05/10/2022ICER to Assess Gene Therapies for Hemophilia A and B
Report will be subject of CTAF meeting in November 2022; Draft Scoping Document open to public comment until May 25, 2022.
05/05/2022The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 300 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Current
Policy Papers.
Easy access to our ongoing policy papers
Barriers to Fair Access
First-ever scorecard of several key appropriate access criteria reveals variation across largest payers but high concordance for clinical eligibility criteria, step therapy, and provider restrictions; lower concordance found for formulary tiering criteria.
Unsupported Price Increases
Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of already high current spending, seven were not supported by new clinical evidence; net price increases on these seven drugs cost Americans an additional $1.67 billion in annual drug spend, of which nearly $1.4 billion was due to a single drug alone: Humira.
Evaluating Reforms to Orphan Drug Development, Pricing, and Coverage
This White Paper presents an analysis of the potential risks and benefits of reforms seeking to strengthen evidence on orphan drugs and to ensure that adequate incentives for orphan drug development are coupled to a more sustainable long-term trajectory for orphan drug pricing.
Latest
Developments.
We’re hiring! Click here to see our full time job listings.
Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.